Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer.
暂无分享,去创建一个
[1] L. Worley,et al. Transducible peptide therapy for uveal melanoma and retinoblastoma. , 2002, Archives of ophthalmology.
[2] D. Sheppard,et al. A novel peptide, PLAEIDGIELTY, for the targeting of α9β1‐integrins , 1998, FEBS Letters.
[3] Ű. Langel,et al. The use of cell-penetrating peptides as a tool for gene regulation. , 2004, Drug discovery today.
[4] Vladimir P Torchilin,et al. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. , 2008, Biopolymers.
[5] T. Sawamura,et al. Identification of Peptides That Target the Endothelial Cell–Specific LOX-1 Receptor , 2001, Hypertension.
[6] R. Lukaszewski,et al. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread. , 2005, Vaccine.
[7] Gong Yang,et al. The inflammatory network: bridging senescent stroma and epithelial tumorigenesis. , 2009, Frontiers in bioscience.
[8] J. Reimann,et al. Peptides containing antigenic and cationic domains have enhanced, multivalent immunogenicity when bound to DNA vaccines , 2004, Journal of Molecular Medicine.
[9] S Uebel,et al. Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Morris,et al. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery. , 2011, Methods in molecular biology.
[11] E. Vivés,et al. Tat peptide-mediated cellular delivery: back to basics. , 2005, Advanced drug delivery reviews.
[12] Roger Y Tsien,et al. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. , 2009, Integrative biology : quantitative biosciences from nano to macro.
[13] R. Reilly,et al. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. , 2006, Bioconjugate chemistry.
[14] Marie Carrière,et al. NLS bioconjugates for targeting therapeutic genes to the nucleus. , 2003, Advanced drug delivery reviews.
[15] M. Morris,et al. Cell-penetrating peptides: tools for intracellular delivery of therapeutics , 2005, Cellular and Molecular Life Sciences CMLS.
[16] M. Imamura,et al. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] Ülo Langel,et al. Design of a Tumor Homing Cell-Penetrating Peptide for Drug Delivery , 2009, International Journal of Peptide Research and Therapeutics.
[18] M. Morris,et al. Cell‐penetrating peptides: from molecular mechanisms to therapeutics , 2008, Biology of the cell.
[19] Xuetao Cao,et al. Systemic genetic transfer of p21WAF−1 and GM-CSF utilizing of a novel oligopeptide-based EGF receptor targeting polyplex , 2003, Cancer Gene Therapy.
[20] W. Seeger,et al. Nano-carriers for DNA delivery to the lung based upon a TAT-derived peptide covalently coupled to PEG-PEI. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[21] Z. Shang,et al. In vitro effects of nitric oxide synthase inhibitor L-NAME on oral squamous cell carcinoma: a preliminary study. , 2006, International journal of oral and maxillofacial surgery.
[22] Steven F. Dowdy,et al. Cell Penetrating Peptides in Drug Delivery , 2004, Pharmaceutical Research.
[23] B. Lebleu,et al. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides , 2010, Cellular and Molecular Life Sciences.
[24] C. Gelfand,et al. Intrinsic peptidase activity causes a sequential multi-step reaction (SMSR) in digestion of human plasma peptides. , 2008, Journal of proteome research.
[25] A. Bolhassani,et al. Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model. , 2011, Experimental parasitology.
[26] Erich A. Nigg,et al. Nucleocytoplasmic transport: signals, mechanisms and regulation , 1997, Nature.
[27] J. Temsamani,et al. The use of cell-penetrating peptides for drug delivery. , 2004, Drug discovery today.
[28] S. Akira,et al. Antigenic Epitopes Fused to Cationic Peptide Bound to Oligonucleotides Facilitate Toll-Like Receptor 9-Dependent, but CD4+ T Cell Help-Independent, Priming of CD8+ T Cells1 , 2003, The Journal of Immunology.
[29] G. Colombo,et al. Rational design of shepherdin, a novel anticancer agent. , 2005, Cancer cell.
[30] Kairong Wang,et al. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. , 2011, Bioconjugate chemistry.
[31] B. Groner,et al. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling , 2003, Journal of Cancer Research and Clinical Oncology.
[32] L. Seymour,et al. Harnessing nuclear localization pathways for transgene delivery. , 2001, Current opinion in molecular therapeutics.
[33] Y. Tseng,et al. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. , 2002, Molecular pharmacology.
[34] K. Rice,et al. Peptide-mediated gene delivery: influence of peptide structure on gene expression. , 1997, Bioconjugate chemistry.
[35] L. Neckers,et al. Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.
[36] Y. Soini,et al. eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma. , 2000, International journal of oncology.
[37] R. Juliano,et al. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[38] R. Kennedy,et al. Induction of nuclear transport with a synthetic peptide homologous to the SV40 T antigen transport signal , 1986, Cell.
[39] M. De Waard,et al. Efficient induction of apoptosis by doxorubicin coupled to cell-penetrating peptides compared to unconjugated doxorubicin in the human breast cancer cell line MDA-MB 231. , 2009, Cancer letters.
[40] A. Bolhassani,et al. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen , 2009, Drug delivery.
[41] V. Apostolopoulos,et al. Cell-penetrating peptides: application in vaccine delivery. , 2010, Biochimica et biophysica acta.
[42] R. Juliano. Challenges to macromolecular drug delivery. , 2007, Biochemical Society transactions.
[43] C. Beattie,et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. , 2009, Cancer research.
[44] Azam Bolhassani,et al. Improvement of different vaccine delivery systems for cancer therapy , 2011, Molecular Cancer.
[45] 千葉 之宣. The novel peptide , 1990 .
[46] M. Manns,et al. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo , 2002, Cancer Gene Therapy.
[47] A. Gartel,et al. The Role of the Cyclin-dependent Kinase Inhibitor p 21 in Apoptosis 1 , 2002 .
[48] Shu Wang,et al. Enhanced gene delivery to PC12 cells by a cationic polypeptide. , 2005, Biomaterials.
[49] Roger Y Tsien,et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. , 2009, Integrative biology : quantitative biosciences from nano to macro.
[50] D. Mukhopadhyay,et al. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. , 2001, Cancer research.
[51] P. Collas,et al. Nuclear localization signal of SV40 T antigen directs import of plasmid DNA into sea urchin male pronuclei in vitro , 1996, Molecular reproduction and development.
[52] H. Moroson. Polycation- treated tumor cells in vivo and in vitro. , 1971, Cancer research.
[53] H. Zentgraf,et al. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. , 2002, Virology.
[54] L. Smith,et al. Peptide-based gene delivery. , 1999, Current opinion in molecular therapeutics.
[55] A. Prochiantz,et al. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. , 1996, Journal of immunology.
[56] E. Kokkoli,et al. Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics. , 2009, Journal of biomechanical engineering.
[57] E. Snyder,et al. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. , 2005, Cancer research.
[58] Yue-Wern Huang,et al. A gene delivery system for human cells mediated by both a cell-penetrating peptide and a piggyBac transposase. , 2011, Biomaterials.
[59] Nucleocytoplasmic Transport , 1996, Science.
[60] F. Alexis,et al. Covalent Attachment of Low Molecular Weight Poly(ethylene imine) Improves Tat Peptide Mediated Gene Delivery , 2006 .
[61] V. Bloomfield,et al. DNA condensation. , 1996, Current opinion in structural biology.
[62] K. Rice,et al. A Potent New Class of Reductively Activated Peptide Gene Delivery Agents* , 2000, The Journal of Biological Chemistry.
[63] R. Werner,et al. Potent enhancement of GFP uptake into HT-29 cells and rat skin permeation by coincubation with tat peptide. , 2011, Journal of pharmaceutical sciences.
[64] Roger D. Kornberg,et al. Synthetic peptides as nuclear localization signals , 1986, Nature.
[65] K. Cahill,et al. Cell-penetrating peptides, electroporation and drug delivery. , 2010, IET systems biology.
[66] Vladimir P Torchilin,et al. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. , 2005, Advanced drug delivery reviews.
[67] Michael I. Wilson,et al. Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[68] Yong Wang,et al. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor–coactivator interactions , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[69] E. Wagner,et al. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice , 2002, Hepatology.
[70] Kevin G. Rice,et al. Peptide-guided gene delivery , 2007, The AAPS Journal.
[71] Benjamin G. Bitler,et al. Anti-cancer therapies that utilize cell penetrating peptides. , 2010, Recent patents on anti-cancer drug discovery.
[72] Ü. Langel,et al. Cell-Penetrating Peptides , 2000, Methods in Molecular Biology.
[73] J. Ajani,et al. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer , 2005, Gastric Cancer.
[74] Sanjeev Banerjee,et al. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. , 2003, Cancer research.
[75] R. Mahato. Non-viral peptide-based approaches to gene delivery. , 1999, Journal of drug targeting.
[76] Joseph Rosenecker,et al. Application of Novel Solid Lipid Nanoparticle (SLN)-Gene Vector Formulations Based on a Dimeric HIV-1 TAT-Peptide in Vitro and in Vivo , 2004, Pharmaceutical Research.
[77] C. Berkland,et al. Calcium condensation of DNA complexed with cell-penetrating peptides offers efficient, noncytotoxic gene delivery. , 2011, Journal of pharmaceutical sciences.
[78] M. Buschle,et al. Binding immune‐stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants , 2002, European journal of immunology.
[79] J. Seelig,et al. The cationic cell-penetrating peptide CPP(TAT) derived from the HIV-1 protein TAT is rapidly transported into living fibroblasts: optical, biophysical, and metabolic evidence. , 2005, Biochemistry.
[80] K. Ingvarsdóttir,et al. Association of the herpes simplex virus major tegument structural protein VP22 with chromatin. , 2010, Biochimica et biophysica acta.
[81] Ernst Wagner,et al. Targeting tumors with non-viral gene delivery systems. , 2002, Drug discovery today.
[82] M. Flessner,et al. Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELP , 2009, Clinical & Experimental Metastasis.
[83] J Barsoum,et al. Tat-mediated delivery of heterologous proteins into cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[84] G. Shipulin,et al. [Progress in gene therapy]. , 2011, Terapevticheskii arkhiv.
[85] J. Butel,et al. Construction and characterization of an SV40 mutant defective in nuclear transport of T antigen , 1984, Cell.
[86] K. Rice,et al. Metabolic stability of glutaraldehyde cross-linked peptide DNA condensates. , 1999, Journal of pharmaceutical sciences.
[87] J. Huo,et al. p53-independent induction of p21waf1/cip1 contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells , 2004, Cell Death and Differentiation.
[88] G. Tang,et al. Gene delivery to tumor cells by cationic polymeric nanovectors coupled to folic acid and the cell-penetrating peptide octaarginine. , 2011, Biomaterials.
[89] Li Jiang,et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation , 2011, Molecular Cancer.
[90] S. Futaki. Membrane-permeable arginine-rich peptides and the translocation mechanisms. , 2005, Advanced drug delivery reviews.
[91] Zhang Ji,et al. C57BL/6および129SvEvマウス間の大動脈弓形状,血行動態,プラークパッターンの相異 | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2009 .
[92] Astrid Gräslund,et al. Mechanisms of Cellular Uptake of Cell-Penetrating Peptides , 2011, Journal of biophysics.
[93] Sanjeev Banerjee,et al. Ursolic Acid Inhibits Nuclear Factor-κB Activation Induced by Carcinogenic Agents through Suppression of IκBα Kinase and p65 Phosphorylation: Correlation with Down-Regulation of Cyclooxygenase 2, Matrix Metalloproteinase 9, and Cyclin D1 , 2003 .